Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD
Recruiting now
Conditions studied: Acute Coronary Syndrome
In brief
The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease. The main question it aims to answer is: Does early (immediately post-event) initiation of a full set of guideline-based, individualized, preventive medication lead to reductions in cardiovascular events compared to current practice (incremental titration strategies)? Researchers will compare the 'first-time-right' strategy group to the current practice group to see if there are improvements in major adverse cardiac and cerebrovascular events (MACE) at 36 months. Participants will: * Receive either the 'first-time-right' strategy or current practice for secondary prevention. * Be monitored (data collection) through routine clinical visits at baseline, 8 weeks, 12, and additional telephone contacts at 24, and 36 months after discharge. * Complete online questionnaires at hospitalization, 8 weeks, 12, 24, and 36 months after discharge.
Key facts
- Study ID
- NCT06637657
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- People needed
- 5586
- Starts
- 2024-07-09
- Expected to finish
- 2029-01-01
- Last updated by the study team
- 2024-10-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- >18 years of age (no upper limit)
- Coronary event, i.e. ACS or coronary revascularisation
- Able to provide informed consent
You may not qualify if…
- (short-term planned) pregnancy or breast feeding
- Dialysis
Where it is running
- Amsterdam UMC — Amsterdam, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.